Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. (17th April 2019)

• Record Type: Journal Article
• Authors: Kromer, Christian; Wilsmann‐Theis, Dagmar; Gerdes, Sascha; Philipp, Sandra; Schaarschmidt, Marthe‐Lisa; Schmieder, Astrid; Dakna, Mohammed; Arnold, Tobias; Peitsch, Wiebke Katharina; Mössner, Rotraut
• Is Part Of: Journal der Deutschen Dermatologischen Gesellschaft. Volume 17:Number 5(2019)
• Page Start: 503
• Page End: 516
• Publication Date: 2019-04-17
• Subjects: Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5005
• DOI: 10.1111/ddg.13834
• Languages: English
• ISSNs: 1610-0379

Abstract

Summary: Background: Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease‐related to psoriasis. Its treatment is challenging, and little is known about the sustainability of different medications. The aim of this study was to analyze drug survival rates and drug discontinuation in the treatment of PPP under real‐world conditions. Patients and Methods: Patients with PPP treated in the dermatology departments of five German university medical centers between 01/2005 and 08/2017 were included in our retrospective study. Drug survival of systemic therapies was assessed with Kaplan‐Meier analysis and multivariate regression. Results: Overall, 347 patients with 935 treatment courses were identified. Within the group of non‐biologic systemic agents, apremilast showed the highest median drug survival (15 months), followed by cyclosporine (12 months), the combination of acitretin and topical PUVA (9 months), MTX (8 months), acitretin monotherapy (6 months), alitretinoin (5 months), and fumaric acid esters (3 months). Among biologicals, the highest maintenance rate was detected for certolizumab pegol (restricted mean: 47.4 months), followed by infliximab (median: 26 months), golimumab (22 months), ustekinumab (21 months), adalimumab (18 months), secukinumab (9 months), and etanercept (8 months). Conclusions: Biologicals and apremilast may serve as second‐line options for treatment of PPP and should be further evaluated.